Biogen Inc. slashed its full-year 2026 earnings guidance by $1.00 per share, projecting revenue between $14.25 billion and $15.25 billion—down mid-single digits from 2025’s $9.89 billion. The biotech firm cited in-process research and development (IPR&D) charges from business development initiatives aimed at growth strategies as the primary drag on near-term performance. Analysts at FactSet estimate the adjusted guidance implies a $15.16 per share average, below the prior $16.25 projection. Notably, the revised outlook excludes potential gains from Biogen’s recent acquisition of Apellis, which the company says will boost adjusted earnings growth through the 2020s once integrated.

The guidance cut follows a first-quarter sales and profit uptick, but Biogen warned that ongoing R&D investments and Apellis integration costs will pressure margins. The move signals a strategic pivot: while the Apellis deal is expected to enhance long-term growth, short-term profitability faces headwinds from development expenses. Investors reacted sharply, driving Biogen’s stock down 8% post-announcement as traders reassessed valuation multiples.

Biogen’s leadership emphasized the acquisition’s strategic value, projecting Apellis will add $2 billion in annual revenue by 2027. However, the IPR&D accounting method—used for early-stage research purchases—created a one-time $1 billion charge, offsetting near-term gains. This aligns with broader industry trends where biotech firms prioritize pipeline expansion over immediate profits, even as shareholders demand clearer timelines for ROI.

The downgrade underscores the tightrope Biogen walks between innovation and execution. With Apellis expected to contribute to a compounded annual growth rate (CAGR) of 12% through 2030, the company bets on science-driven bets despite quarterly volatility. For now, the market will scrutinize whether the $14.25 billion floor holds as a realistic benchmark amid sector-wide profit-taking.